Henoch-Schönlein purpura laboratory findings

Henoch-Schönlein purpura Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Henoch-Schönlein purpura from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Henoch-Schönlein purpura laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Henoch-Schönlein purpura laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Henoch-Schönlein purpura laboratory findings
CDC on Henoch-Schönlein purpura laboratory findings
Henoch-Schönlein purpura laboratory findings in the news
Blogs on Henoch-Schönlein purpura laboratory findings
Directions to Hospitals Treating Henoch-Schönlein purpura
Risk calculators and risk factors for Henoch-Schönlein purpura laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Laboratory findings

• There is no specific diagnostic test available for HSP.
• Platelet count, coagulation studies such as PT, aPTT, and BT is done to rule out other diseases like coagulopathies. They are usually normal.
• Urinalysis, is done to check for any blood in the urine or proteinuria for renal involvement.
• Serum IgA levels are elevated in the majority of patients with HSP, and in patients with renal involvement higher IgA levels are detected.
• The routine blood tests CBC (complete blood count), metabolic profile, urinalysis are usually inconclusive.
• Patients with occult GI bleeding may have anemia.
• Since HSP is a type-III hypersensitivity reaction complements are consumed by the immune complexes eventually leading to hypocomplementemia (decreased C3 and C4).
• Leukocytosis and elevated acute phase reactants are noted in patients with HSP secondary to bacterial infections.